1. Home
  2. Medical Research
  3. Albany, NY
  4. Regenerative Research Foundation

Regenerative Research Foundation

Regenerative Research Foundation is ranked among medical research organizations in Albany, NY, with an America's Best Score of 72 out of 100, based on its 2025 Form 990.

  • Albany, NY
  • Tax-exempt since 2007
  • EIN: 20-3654626
neuralsci.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
72OF 100 Ranked in Albany Medical Research How this score is calculated

Organization summary

Regenerative Research Foundation is a 501(c)(3) organization, classified under Medical Research (NTEE H96). Contributions are tax-deductible.

150 New Scotland Ave, Albany, NY 12208-3423

Among the 3 scored medical research organizations in Albany, Regenerative Research Foundation holds 11.7 months of operating reserves (peer median 11.7 months), runs a typical yearly surplus of 16.5% (peers: surplus of 16.5%), and has grown spending 6.6% a year (peers: grown spending 6.6% a year).

In fiscal year 2025 it reported $7,965,326 in revenue and $7,076,763 in expenses, with contributions making up 92.9% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

The principal mission of the Regenerative Research Foundation is to develop regenerative STEM cell therapies for diseases of the central nervous system (cns): The brain, spinal cord, and retina.

Largest programs · fiscal year 2025

  • Despite many challenges in fiscal year 2025 the Regenerative Research Foundation continued to pursue its research mission. During the year foundation researchers published thirteen articles in prominent scientific journals reporting the results of their investigations into neurodegenerative diseases such as dementia, macular degeneration and potential treatments for neurodegenerative diseases. The… Read more

    Despite many challenges in fiscal year 2025 the Regenerative Research Foundation continued to pursue its research mission. During the year foundation researchers published thirteen articles in prominent scientific journals reporting the results of their investigations into neurodegenerative diseases such as dementia, macular degeneration and potential treatments for neurodegenerative diseases. These publications are available to the research community and general public free of charge through the national library of medicine open access repository. The foundation researchers continue to prepare funding applications which will support their research activities. The foundation continued to develop and improve its production of human STEM cell organoid models as an alternative to the use of animal models. These efforts are endorsed by the nih and fda complement-arie initiatives that promote new approach methodology (nam) to reduce animal use in drug development. The foundation's core facility, neuracell, continues to provide brain region-specific organoids to researchers around the country.

    $1,012,342 spent · 16.5% of program spending
  • The continuing phase 1/2a clinical trial treated its 12th subject completing the second cohort of an 18-subject trial. The foundation's scientific director, dr. Sally temple-stern, delivered the closing keynote address at the 2026 association for research in vision and ophthalmology meeting (the major meeting for ophthalmic research). The safety and efficacy results of the low dose phase of the tr… Read more

    The continuing phase 1/2a clinical trial treated its 12th subject completing the second cohort of an 18-subject trial. The foundation's scientific director, dr. Sally temple-stern, delivered the closing keynote address at the 2026 association for research in vision and ophthalmology meeting (the major meeting for ophthalmic research). The safety and efficacy results of the low dose phase of the trial were published during the year 2025.

    $1,013,548 spent · 16.5% of program spending
  • The alzheimer's disease and related dementias research program continues its mission to expand the understanding and development of a potential treatment for these neurodegenerative diseases. The institute continues to serve as the lead organization for a consortium of institutions and investigators funded by the national institutes of health and other private foundations which is focused on ident… Read more

    The alzheimer's disease and related dementias research program continues its mission to expand the understanding and development of a potential treatment for these neurodegenerative diseases. The institute continues to serve as the lead organization for a consortium of institutions and investigators funded by the national institutes of health and other private foundations which is focused on identifying genes associated with the development of dementia. The foundation continues its search for a biotech partner to support research and development of a promising neurodegenerative disease treatment under development by the foundation.

    $4,103,203 spent · 66.9% of program spending

Where each dollar went · fiscal year 2025

Of every dollar it spent, 87¢ went to programs, 13¢ to management and 0¢ to fundraising.

  • Programs $6,129,093
  • Management $938,337
  • Fundraising $9,333

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score72 / 100
DesignationRanked

Score breakdown

MeasureThis organizationPoints
Operating reserves11.7 mo; 11.2 mo in cash8.1 / 25
Financial balance (median margin)+16.5%20 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth+6.6% / yr10.8 / 15
Track record19 years7.6 / 10
Debt load32.3% of assets5.5 / 10
Total72.1 → 72
Spending on programs
Not scored; America's Best needs 65%+
87%Meets

Compared with Albany peers

MeasureThis organizationPeer median
Operating reserves11.7 mo11.7 mo
Typical margin+16.5%+16.5%
Spending growth+6.6% / yr+6.6% / yr
Debt load32.3%32.3%

Peers: the 3 Albany medical research organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$7,965,326Fiscal year 20252022: $7,532,14920222023: $8,795,24520232024: $7,006,53820242025: $7,965,3262025
Expenses$7,076,763Fiscal year 20252022: $5,849,24720222023: $7,305,10620232024: $6,491,04820242025: $7,076,7632025
Total assets$10,216,177Fiscal year 20252022: $5,981,94920222023: $6,996,42520232024: $9,028,49420242025: $10,216,1772025
Total liabilities$3,299,474Fiscal year 20252022: $1,959,43820222023: $1,483,77520232024: $3,000,35420242025: $3,299,4742025
Fiscal year ending December 2025
Revenue$7,965,326
Expenses$7,076,763
Net income$888,563
Net assets$6,916,703

Notable sources of revenue

Percent of total revenue
Contributions$7,396,591
Program services$250,843
Investment income$133,890
Other (net)$184,002

Assets / debt

Total assets$10,216,177
Total liabilities$3,299,474
Net assets$6,916,703

Compensation

Not in our extract for this year.

Fiscal year ending December 2024
Revenue$7,006,538
Expenses$6,491,048
Net income$515,490
Net assets$6,028,140

Notable sources of revenue

Percent of total revenue
Contributions$5,982,290
Program services$782,345
Investment income$75,008
Other (net)$166,895

Assets / debt

Total assets$9,028,494
Total liabilities$3,000,354
Net assets$6,028,140

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$8,795,245
Expenses$7,305,106
Net income$1,490,139
Net assets$5,512,650

Notable sources of revenue

Percent of total revenue
Contributions$7,786,967
Program services$700,000
Investment income$57,424
Other (net)$250,854

Assets / debt

Total assets$6,996,425
Total liabilities$1,483,775
Net assets$5,512,650

Compensation

Officers and key employees$243,832
Share of expenses3.3%
Fiscal year ending December 2022
Revenue$7,532,149
Expenses$5,849,247
Net income$1,682,902
Net assets$4,022,511

Notable sources of revenue

Percent of total revenue
Contributions$6,469,338
Program services$577,571
Investment income$204
Other (net)$485,036

Assets / debt

Total assets$5,981,949
Total liabilities$1,959,438
Net assets$4,022,511

Compensation

Officers and key employees$230,939
Share of expenses3.9%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?